News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Antoinette R. Tan

Articles by Antoinette R. Tan

22 Updated Results From VERITAC Evaluating Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer

22 Updated Results From VERITAC Evaluating Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer

BySara A. Hurvitz, MD,Anne F. Schott, MD,Cynthia X. Ma, MD, PhD,Rita Nanda, MD,George Zahrah,Natasha Hunter, MD,Antoinette R. Tan,Melinda L. Telli, MD,Jesus Anampa Mesias,Rinath M. Jeselsohn,Pamela N. Munster, MD,Eric Zhi,Elizabeth Duperret,Cecile Mather,Erika P. Hamilton, MD,Hyo S Han

August 4th 2024

24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study

BySara A. Hurvitz, MD,Anne F. Schott, MD,Cynthia X. Ma, MD, PhD,Erika P. Hamilton, MD,Rita Nanda, MD,George Zahrah,Natasha Hunter, MD,Antoinette R. Tan,Melinda L. Telli, MD,Jesus Anampa Mesias,Rinath Jeselsohn,Pamela N. Munster, MD,Haolan Lu,Richard Gedrich,Cecile Mather,Janaki Parameswaran,Hyo S Han

April 27th 2023

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Niraparib Regimen in BRCA2+ Metastatic CSPC

ASH 2025: The Top 10 Takeaways for Hematologic Oncology Care

PFS Continues to Improve With Imlunestrant in Advanced Breast Cancer

EMD Associated With Poorer Outcomes in Previously Treated R/R Multiple Myeloma

QOL Improvement in Breast Cancer Noted With YES System

© 2025 MJH Life Sciences^®

All rights reserved.